The EQUULEUS Trial: DARZALEX® + Pd After 2 Prior MM Therapies

Share

DARZALEX® + Pomalyst® (pomalidomide) + dexamethasone

A multicenter, open-label phase 1b study1,2

Patients had received prior treatment with a proteasome inhibitor (PI) and an immunomodulatory agent1

 

  • This trial included 103 patients who received DARZALEX® 16 mg/kg in combination with Pd and were treated with pre- and post-infusion medications. Patients were treated until disease progression or unacceptable toxicity1,3
  • Patients had a median of 4 prior lines of therapy1
  • Of the patients who were tested for cytogenetics, 74.7% were standard risk and 25.3% were high risk3

Patients were refractory to prior therapies1*

  • 89% to lenalidomide
  • 71% to bortezomib
  • 64% to bortezomib and lenalidomide
*Plesase note that this is not a full list of prior therapies.

 

Patient Characteristics

 

ECOG=Eastern Cooperative Oncology Group.